MIST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MIST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the three months ended in Mar. 2024, Milestone Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $52.51 Mil on purchasing investments. It gained $25.50 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $0.00 Mil from other investing activities. In all, Milestone Pharmaceuticals spent $27.01 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.
The historical data trend for Milestone Pharmaceuticals's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Milestone Pharmaceuticals Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash Flow from Investing | Get a 7-Day Free Trial | -0.38 | -70.00 | 70.00 | -57.12 | 4.76 |
Milestone Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Flow from Investing | Get a 7-Day Free Trial | 29.97 | -28.03 | -10.86 | 13.68 | -27.01 |
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Milestone Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:
Milestone Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:
Cash Flow from Investing | (Q: Mar. 2024 ) | ||||
= | Purchase Of Property, Plant, Equipment | + | Sale Of Property, Plant, Equipment | + | Purchase Of Business |
= | 0 | + | 0 | + | 0 |
+ | Sale Of Business | + | Purchase Of Investment | + | Sale Of Investment |
+ | 0 | + | -52.514 | + | 25.5 |
+ | Net Intangibles Purchase And Sale | + | Cash From Discontinued Investing Activities | + | Cash From Other Investing Activities |
+ | 0 | + | 0 | + | 3.5527136788005E-15 |
= | -27.01 |
Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-52.23 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Milestone Pharmaceuticals (NAS:MIST) Cash Flow from Investing Explanation
Cash flow from investing contains nine items:
1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.
Milestone Pharmaceuticals's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Milestone Pharmaceuticals spent $0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.
Milestone Pharmaceuticals's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means Milestone Pharmaceuticals gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Milestone Pharmaceuticals's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Milestone Pharmaceuticals spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Milestone Pharmaceuticals's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Milestone Pharmaceuticals gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Milestone Pharmaceuticals's purchase of investment for the three months ended in Mar. 2024 was $-52.51 Mil. It means Milestone Pharmaceuticals spent {stock_data.stock.currency_symbol}}52.51 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Milestone Pharmaceuticals's sale of investment for the three months ended in Mar. 2024 was $25.50 Mil. It means Milestone Pharmaceuticals gained $25.50 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Milestone Pharmaceuticals's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means Milestone Pharmaceuticals paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Milestone Pharmaceuticals's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Milestone Pharmaceuticals paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Milestone Pharmaceuticals's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means Milestone Pharmaceuticals received $0.00 Mil from other investing activities.
Thank you for viewing the detailed overview of Milestone Pharmaceuticals's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
David Bharucha | officer: Chief Medical Officer | C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6 |
Debra K. Liebert | director | C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTR?AL A8 H4M 2X6 |
Richard C Pasternak | director | C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M2X6 |
Michael John Tomsicek | director | 28 OVERLOOK DRIVE, BEDFORD MA 01730 |
Robert James Wills | director | 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103 |
Roderick Wong | 10 percent owner | C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Rtw Investments, Lp | 10 percent owner | 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014 |
Jeffrey Edward Nelson | officer: Chief Operating Officer | C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6 |
Paul F Truex | director | PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Lisa M. Giles | director | DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606 |
Fonds De Solidarite Des Travailleurs Du Quebec | 10 percent owner | 545 CREMAZIE BLVD. EAST, SUITE 200, MONTREAL A8 H2M 2W4 |
Novo Holdings A/s | 10 percent owner, other: SEE REMARKS | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Amit Hasija | officer: CFO & EVP of Corp. Development | C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL A8 H4M 2X6 |
Lorenz Muller | officer: Chief Commercial Officer | C/O MILESTONE PHARMACEUTICALS, INC., 1111 DR. FREDERIK-PHILIPS BLVD., STE 420, MONTREAL A8 H4M 2X6 |
From GuruFocus
By Business Wire • 12-26-2023
By PRNewswire • 11-14-2023
By PRNewswire • 01-07-2024
By PRNewswire • 01-23-2024
By PRNewswire PRNewswire • 10-17-2022
By PRNewswire • 11-14-2023
By PRNewswire • 11-14-2023
By PRNewswire • 12-30-2023
By PRNewswire PRNewswire • 06-20-2023
By PRNewswire • 11-21-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.